Atypical antipsychotics show a broader spectrum of efficacy and fewer adverse effects than older/typical neuroleptics. Therefore, they are used as the first-choice treatment for patients suffering from schizophrenia. Concerning the acute effects, no differences among the group of new antipsychotics have been demonstrated so far. Thus, the most important criteria for choosing an antipsychotic for an individual patient are the expected side effects resulting from different receptor-binding properties. Today, no new antipsychotic can be considered as first-choice treatment for all patients. Outcome criteria should not only include psychopathology, relapse and rehospitalization, but also side effects, neuropsychological parameters and compliance, as well as self-rated well-being and quality of life.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/14737175.2.3.355 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Utilization of Potentially Inappropriate Sedative-Hypnotic and Atypical Antipsychotic Medications among Elderly Individuals with Insomnia and Alzheimer's Disease.
Sleep
January 2025
Complete HEOR Solutions (CHEORS), Chalfont, PA, USA.
Study Objectives: This study assessed the utilization of potentially inappropriate medications (PIM) including oral sedative-hypnotic and atypical antipsychotic (OSHAA), healthcare resource utilization (HCRU), and costs among elderly individuals with insomnia and in the subpopulation with Alzheimer's Disease (AD) who also had a diagnosis of insomnia.
Methods: Using claims database containing International Classification of Diseases, 10th Revision (ICD-10) codes, the cohort included individuals aged ≥ 65 with incident insomnia (EI, N=152,969) and AD insomnia subpopulation (ADI, N=4,888). Proportion of patients utilizing atypical antipsychotics or oral sedative-hypnotic medications, namely z-drugs, benzodiazepines, doxepin, Dual Orexin Receptor Antagonists (DORAs), and melatonin agonists, were assessed.
Drug-Induced Myoclonus: A Systematic Review.
Medicina (Kaunas)
January 2025
Neurology Department, Cooper University Hospital, Camden, NJ 08103, USA.
: Myoclonus is already associated with a wide variety of drugs and systemic conditions. As new components are discovered, more drugs are suspected of causing this disabling abnormal involuntary movement. This systematic review aims to assess the medications associated with drug-induced myoclonus (DIM).
View Article and Find Full Text PDFHealthcare resource utilization and costs of using Cariprazine as the first versus subsequent adjunctive therapy for major depressive disorder.
J Med Econ
January 2025
AbbVie, North Chicago, IL, USA.
Aim: Inadequate response to antidepressant therapy (ADT) is common in major depressive disorder (MDD); atypical antipsychotic (AA) adjunctive therapy may be effective for these patients. This study aimed to compare healthcare resource utilization (HRU) and costs between patients initiating the AA cariprazine as their first adjunctive therapy vs those initiating cariprazine subsequently.
Methods: The Merative MarketScan® Commercial Database (January 1, 2015, to June 30, 2021) was used to identify US adults with MDD and ≥1 pharmacy claim for cariprazine adjunctive to ADT in 2018 or after.
Successful Clozapine Treatment for Treatment-Resistant Schizophrenia With Zinc Deficiency Severe Anemia: A Case Report.
Neuropsychopharmacol Rep
March 2025
Department of Neuropsychiatry, School of Medicine, Wakayama Medical University, Wakayama, Wakayama, Japan.
Introduction: Clozapine is an atypical antipsychotic drug approved for treatment-resistant schizophrenia (TRS). Despite its high efficacy for TRS, clozapine is associated with several serious adverse effects, such as neutropenia and diabetes, so it requires vigilant monitoring. Severe anemia has also been documented as a rare but serious complication with an unclear mechanism.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!